On August 1, 2024, Shattuck Labs, Inc., a clinical-stage biotechnology company, announced its financial results for the second quarter ended June 30, 2024. The company reported a net loss of $21.5 million, or $0.42 per share, compared to a net loss of $21.3 million, or $0.50 per share, for the same period in the previous year. Research and Development expenses increased slightly to $19.2 million, while General and Administrative expenses rose to $5.3 million. The company's cash and cash equivalents, along with investments, totaled $105.3 million, a decrease from $117.2 million the previous year. Shattuck Labs also highlighted its clinical progress, including positive interim data from a Phase 1B trial of SL-172154 in combination with Azacitidine for treating HR-MDS and TP53 mutant AML patients. The company has been granted Orphan Drug...Show More

On August 1, 2024, Shattuck Labs, Inc., a clinical-stage biotechnology company, announced its financial results for the second quarter ended June 30, 2024. The company reported a net loss of $21.5 million, or $0.42 per share, compared to a net loss of $21.3 million, or $0.50 per share, for the same period in the previous year. Research and Development expenses increased slightly to $19.2 million, while General and Administrative expenses rose to $5.3 million. The company's cash and cash equivalents, along with investments, totaled $105.3 million, a decrease from $117.2 million the previous year. Shattuck Labs also highlighted its clinical progress, including positive interim data from a Phase 1B trial of SL-172154 in combination with Azacitidine for treating HR-MDS and TP53 mutant AML patients. The company has been granted Orphan Drug Designation by the FDA for SL-172154 for AML treatment. Enrollment for a randomized controlled Phase 1B dose-expansion cohort in HR-MDS patients is ongoing. Shattuck Labs also reported on its Phase 1B trial of SL-172154 in Platinum-Resistant Ovarian Cancer, with partial responses observed in some patients. The company was added to the Russell 2000® and Russell 3000® Indexes and anticipates its current funds will sustain operations into 2026, beyond the results from its Phase 1 clinical trials of SL-172154.